Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

Astellas Pharma Inc. (ALPMY) Stock Price, News, Quote & History

New Canadian Real-World Evidence at ESMO 2026 Highlights Integration of CLDN18.2 Testing and Targeted Treatment in Clinical Practice

Astellas Pharma Inc. (ALPMY) stock price, news, quote and history

AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million

Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?

Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

New Preliminary Real-World VEOZAH™ (fezolinetant) Data Highlights Improvements in Menopause-Related Symptoms and Sleep Outcomes

Astellas Pharma Inc's Dividend Analysis

ARTHEx Biotech Announces Appointment of Glenn P. Sblendorio as Chairman of the Board

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Astellas Pharma Inc. 2027 Q1 - Results - Earnings Call Presentation (OTCMKTS:ALPMY) 2026-08-05

Is Astellas Pharma (ALPMY) Stock Undervalued Right Now?